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Staphylococcus aureus is the leading cause of human skin infections. In this issue of Cell Host &
Microbe, new researchprobes howa change in surface hydrophobicitymediated by a singleS. aureus
protein renders the pathogen resistant to key molecular effectors of skin innate immunity, including
cationic antimicrobial peptides and fatty acid constituents of sebum. Novel treatment strategies for
S. aureus infection may lie in supplementing the very same innate defense molecules to therapeutic
levels.In a complex environment, higher or-
ganisms, including humans, exist in
perpetual contact with diverse micro-
bial species. Our outermost layer, the
skin, mediates a large proportion of
these encounters. The common out-
come is transient and innocuous; im-
pervious to water, the keratinized skin
epithelium physically restricts access
of microbes to deeper tissues. The
barrier function of the skin is further
enhanced by soluble antimicrobial de-
fense molecules synthesized at low
levels under resting conditions (e.g.,
in sweat) and greatly induced following
any break in epithelial integrity. These
include the antimicrobial peptides
cathelicidin,b-defensin, lysozyme, and
dermcidin, together active against a
broad array of bacterial and fungal
species and certain enveloped vi-
ruses. Rarely, the interaction between
microbe and our skin produces an un-
toward outcome—infection. When this
occurs, the culprit more often than not
is Staphylococcus aureus. The formi-
dable capacity of this singular patho-
gen to resist the multifaceted innate
immune defenses of human skin fasci-
nates microbiologists as much as it
vexes physicians. A new facet of this
dynamic is explored by Clarke et al.
in this issue of Cell Host & Microbe
(Clarke et al., 2007).
The iron-responsive surface deter-
minant A (IsdA) protein is anchored via
its C terminus to the peptidoglycan of
the S. aureus cell wall by the action of
sortase enzymes (Mazmanian et al.,2002). Coordinately induced with other
bacterial factors in response to iron
restriction, IsdA contains a so-called
NEAT (near iron transporter) domain
forming a clathrin adaptor-like b sand-
wich fold and hydrophobic pocket that
binds heme in a 1:1 ratio (Grigg et al.,
2007). While a likely role in S. aureus
iron acquisition is only partially under-
stood, additional intriguing features of
the IsdA protein have been revealed
through a series of careful targeted
mutagenesis and heterologous ex-
pression studies. Simon Clarke, Simon
Foster, and colleagues have shown
that the IsdA NEAT domain also medi-
ates physiologically relevant binding of
S. aureus to the extracellular matrix
components fibronectin and fibrino-
gen (Clarke et al., 2004), contributing
to the ability of the pathogen to colo-
nize the nasal mucosa in the cotton
rat model (Clarke et al., 2006). Now,
the research group has identified a fas-
cinating contribution of IsdA expres-
sion to the biophysical properties of
the S. aureus cell surface (Clarke
et al., 2007). By reducing the overall
hydrophobicity of the bacterium, IsdA
blocks the action of several antibacte-
rial molecules present in normal skin,
including cathelicidin and b-defensin
peptides, human sebum, and its con-
stituent hydrophobic fatty acids. Con-
sequently, IsdA promotes S. aureus
survival on human skin. Analysis of
deletion constructs revealed that the
IsdA domain mediating decreased hy-
drophobicity and resistance to innateCell Host & Microimmune defense molecules is distinct
from the NEAT domain and situated
toward the protein’s C terminus (Fig-
ure 1).
Clarke et al. have also documented
IsdA promotion of S. aureus resistance
to certain bacteriocins (lantibiotics),
antimicrobial peptides of bacterial
origin (Clarke et al., 2007). The primary
constituents of the normal human skin
microflora are coagulase negative
staphylococci such as S. epidermidis,
and these organisms produce bacte-
riocins with in vitro activities against
S. aureus. An overlooked element of
normal skin innate immunity may be
the recruitment of commensal bacteria
capable of participating in defense
against potential pathogens. A logical
area for future study would be to
examine whether IsdA in fact allows
S. aureus to resist S. epidermidis bac-
teriocins and compete for a niche
alongside the dominant microflora.
A most interesting aspect of the new
observations of Clarke et al. is a re-
emphasis of the importance of sebum
lipids as a dynamic aspect of skin in-
nate immunity. Like antimicrobial pep-
tides, fatty acids are induced in skin
upon injury or microbial stimuli through
Toll-like receptor-dependent path-
ways (Schauber et al., 2007; Georgel
et al., 2005), and knockout mice defi-
cient in biosynthesis of either compo-
nent fail to restrict bacterial prolifera-
tion (Nizet et al., 2001; Georgel et al.,
2005). Reduced levels of sebum fatty
acids as well as antimicrobial peptidesbe 1, May 2007 ª2007 Elsevier Inc. 161
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PreviewsFigure 1. Multiple Potential Contributions of the Surface-Expressed IsdA Protein to
Staphylococcus aureus Pathogenesisare seen in atopic dermatitis (eczema),
an inflammatory skin condition predis-
posed to recurrent bacterial infection
(Takigawa et al., 2005; Ong et al.,
2002). While several mechanisms of
S. aureus resistance to antimicrobial
peptides have been described (i.e.,
cell wall charge modifications, pro-
teolytic inactivation, extracellular trap-
ping), the hydrophobicity-modifying
properties of IsdA represent the first
identified molecular resistance mech-
anism of the pathogen to host fatty
acid defenses. Clarke et al. have also
identified several novel effects exerted
by subinhibitory levels of sebum fatty
acids on S. aureus, including de-
creased transcription of genes encod-
ing virulence factors and an antibiotic
resistance determinant; these pro-
cesses are similarly blocked by IsdA.
Can one get too much of a good
thing? Recognizing the implicit impor-
tance of sebum lipids in innate immu-
nity, the authors tested pharmacologic
administration of the constituent fatty162 Cell Host & Microbe 1, May 2007 ª2acid C-6-H in topical and systemic
S. aureus murine infection models,
documenting significant reductions
in bacterial loads, and apparently
overcoming any protection IsdA
afforded the bacterium. Whether this
therapeutic benefit reflects direct
bactericidal or bacteriostatic activity,
transcriptional or posttranslational in-
terference with virulence factor pro-
duction or action, or an unanticipated
propitious effect on host immune func-
tion remains to be proven. Neverthe-
less, it raises an interesting concept.
Natural products form the basis of the
vast majority of effective antibiotic
treatments in medical practice, in par-
ticular those derived from the second-
ary metabolites of microbes such as
the Penicillium mold or soil actinomy-
cetes. If we can appreciate a pimple
not as a cosmetic woe, but rather as
a focused confluence of innate im-
mune molecules, a new generation of
natural product antibiotics could be
staring us right in the mirror.007 Elsevier Inc.This study reminds us that in an im-
portant sense, immunity is only skin
deep. The indifference of S. aureus
to many of the key effectors of skin
innate defense undoubtedly accounts
for its status as the foremost etiologic
agent of infection in both normal and
wounded human skin, which may ac-
count for over 11 million doctor visits
each year in the U.S. alone (McCaig
et al., 2006). Continued identification
of the specific virulence factors of
this leading cutaneous pathogen (and
of those vulnerabilities in skin innate
defense that it exploits) promises new
therapeutic approaches in an era of
increasing resistance to classical anti-
biotics.
REFERENCES
Clarke, S.R., Wiltshire, M.D., and Foster, S.J.
(2004). Mol. Microbiol. 51, 1509–1519.
Clarke, S.R., Brummell, K.J., Horsburgh, M.J.,
McDowell, P.W., SyedMohamed, S.A., Staple-
ton, M.R., Acevedo, J., Read, R.C., Day, N.P.,
Peacock, S.J., et al. (2006). J. Infect. Dis.
193, 1098–1108.
Clarke, S.R., Mohamed, R., Bian, L., Routh,
A.F., Kokai-Kun, J.F., Mond, J.J., Tarkowski,
A., and Foster, S.J. (2007). Cell Host & Microbe
1, this issue, 199–212.
Georgel, P., Crozat, K., Lauth, X., Makranto-
naki, E., Seltmann, H., Sovath, S., Hoebe, K.,
Du, X., Rutschmann, S., Jiang, Z., et al.
(2005). Infect. Immun. 73, 4512–4521.
Grigg, J.C., Vermeiren, C.L., Heinrichs, D.E.,
and Murphy, M.E. (2007). Mol. Microbiol. 63,
139–149.
Mazmanian, S.K., Ton-That, H., Su, K., and
Schneewind, O. (2002). Proc. Natl. Acad. Sci.
USA 99, 2293–2298.
McCaig, L.F., McDonald, L.C., Mandal, S., and
Jernigan, D.B. (2006). Emerg. Infect. Dis. 12,
1715–1723.
Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J.,
Rudisill, J., Dorschner, R.A., Pestonjamasp, V.,
Piraino, J., Huttner, K., and Gallo, R.L. (2001).
Nature 414, 454–457.
Ong, P.Y., Ohtake, T., Brandt, C., Strickland,
L., Boguniewics, M., Ganz, T., Gallo, R.L.,
and Leung, D.Y. (2002). N. Engl. J. Med. 347,
1151–1160.
Schauber, J., Dorschner, R.A., Coda, A.B.,
Buchau, A.S., Liu, P.T., Kiken, D., Helfrich,
Y.R., Kang, S., Elileah, H.Z., Steinmeyer, A.,
et al. (2007). J. Clin. Invest. 117, 803–811.
Takigawa, H., Nakagawa, H., Kuzukawa, M.,
Mori, H., and Imokawa, G. (2005). Dermatology
211, 240–248.
